Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:CRON NASDAQ:CRVS NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.56-0.8%$2.95$2.41▼$13.99$239.09M1.21.50 million shs758,325 shsCRONCronos Group$2.72+0.9%$2.70$1.87▼$3.43$1.00B0.891.09 million shs1.05 million shsCRVSCorvus Pharmaceuticals$12.96+2.6%$13.57$3.71▼$26.95$1.06B0.841.35 million shs1.04 million shsSPRYARS Pharmaceuticals$10.54+2.5%$8.70$6.66▼$18.90$1.02B0.941.42 million shs1.91 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-1.16%-4.12%-4.83%-11.11%-73.22%CRONCronos Group+0.56%+1.69%-0.91%+7.74%+43.65%CRVSCorvus Pharmaceuticals+2.63%+8.02%+2.79%-7.87%+198.66%SPRYARS Pharmaceuticals+2.53%+6.46%+32.75%+23.13%-37.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.56-0.8%$2.95$2.41▼$13.99$239.09M1.21.50 million shs758,325 shsCRONCronos Group$2.72+0.9%$2.70$1.87▼$3.43$1.00B0.891.09 million shs1.05 million shsCRVSCorvus Pharmaceuticals$12.96+2.6%$13.57$3.71▼$26.95$1.06B0.841.35 million shs1.04 million shsSPRYARS Pharmaceuticals$10.54+2.5%$8.70$6.66▼$18.90$1.02B0.941.42 million shs1.91 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-1.16%-4.12%-4.83%-11.11%-73.22%CRONCronos Group+0.56%+1.69%-0.91%+7.74%+43.65%CRVSCorvus Pharmaceuticals+2.63%+8.02%+2.79%-7.87%+198.66%SPRYARS Pharmaceuticals+2.53%+6.46%+32.75%+23.13%-37.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 2.40Hold$21.33733.33% UpsideCRONCronos Group 2.20Hold$2.30-15.29% DownsideCRVSCorvus Pharmaceuticals 2.71Moderate Buy$33.33157.16% UpsideSPRYARS Pharmaceuticals 2.50Moderate Buy$28.60171.35% UpsideCurrent Analyst Ratings BreakdownLatest AVXL, CRON, CRVS, and SPRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026CRONCronos Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/28/2026SPRYARS Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$12.00 ➝ $30.005/27/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/15/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026CRONCronos Group TD SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/4/2026AVXLAnavex Life Sciences Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.004/29/2026CRVSCorvus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.10 per shareN/ACRONCronos Group$146.59M6.91$0.01 per share214.57$3.00 per share0.91CRVSCorvus PharmaceuticalsN/AN/A$0.13 per share99.64$0.73 per shareN/ASPRYARS Pharmaceuticals$84.28M12.42N/AN/A$1.16 per share9.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$46.38M-$0.46N/AN/AN/AN/A-38.76%-35.01%6/30/2026 (Estimated)CRONCronos Group-$9.45M$0.01271.77N/AN/A-1.14%-1.26%-1.20%8/6/2026 (Estimated)CRVSCorvus Pharmaceuticals-$15.28M-$0.52N/AN/AN/AN/A-38.92%-35.75%8/6/2026 (Estimated)SPRYARS Pharmaceuticals-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)Latest AVXL, CRON, CRVS, and SPRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/30/2026Q2 2026AVXLAnavex Life Sciences-$0.07-$0.07N/AN/AN/AN/A5/15/2026Q1 2026SPRYARS Pharmaceuticals-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million5/11/2026Q1 2026CRONCronos Group$0.01$0.01N/A$0.04$42.20 million$58.97 million5/7/2026Q1 2026CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A20.8720.87CRONCronos GroupN/A21.8720.73CRVSCorvus PharmaceuticalsN/A19.8119.81SPRYARS Pharmaceuticals2.794.944.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%CRONCronos Group8.71%CRVSCorvus Pharmaceuticals46.64%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%CRONCronos Group7.80%CRVSCorvus Pharmaceuticals19.70%SPRYARS Pharmaceuticals33.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4092.67 million82.11 millionOptionableCRONCronos Group450373.03 million343.94 millionOptionableCRVSCorvus Pharmaceuticals3084.09 million67.52 millionOptionableSPRYARS Pharmaceuticals9099.30 million65.74 millionOptionableAVXL, CRON, CRVS, and SPRY HeadlinesRecent News About These CompaniesSPRY stock tanks over 23% after-hours — ARS Pharmaceuticals reports no new major insurance wins for Neffy1 hour ago | msn.comARS Pharmaceuticals Provides Commercial and Financial UpdatesJune 24 at 4:05 PM | globenewswire.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 23 at 4:18 AM | americanbankingnews.comCreek Drive Management Group LLC Makes New Investment in ARS Pharmaceuticals, Inc. $SPRYJune 21, 2026 | marketbeat.comEversept Partners LP Cuts Stake in ARS Pharmaceuticals, Inc. $SPRYJune 18, 2026 | marketbeat.comGeneral American Investors Co. Inc. Takes $6.52 Million Position in ARS Pharmaceuticals, Inc. $SPRYJune 14, 2026 | marketbeat.comInsider Selling: ARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells 3,355 Shares of StockJune 13, 2026 | insidertrades.comHow The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future ValuationJune 9, 2026 | finance.yahoo.comDrew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe AllergiesJune 4, 2026 | finance.yahoo.comWhy ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Up 5.30%May 20, 2026 | aaii.comAARS Pharmaceuticals: Still A Buy As Neffy Access ImprovesMay 20, 2026 | seekingalpha.comArs Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access programMay 16, 2026 | seekingalpha.comARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 16, 2026 | finance.yahoo.comARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue EstimatesMay 15, 2026 | zacks.comARS Pharmaceuticals Reports Q1 2026 Financial Results Highlighting $22.7 Million in Revenue and Progress on neffy® CommercializationMay 15, 2026 | quiverquant.comQARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate UpdateMay 15, 2026 | globenewswire.comARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMay 15, 2026 | benzinga.comARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMay 15, 2026 | benzinga.comARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as PresidentMay 13, 2026 | globenewswire.comARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Stocks Rallying on Micron's Price Boost: Substance or Hype?By Dan Schmidt | May 28, 2026Micron’s $1 Trillion Memory Melt-UpBy Jeffrey Neal Johnson | May 27, 2026Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?By Jessica Mitacek | June 1, 2026If the Market Rally Stalls, This ETF Can Insulate PortfoliosBy Jessica Mitacek | May 28, 2026AVXL, CRON, CRVS, and SPRY Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$2.56 -0.02 (-0.78%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$2.60 +0.04 (+1.45%) As of 06/24/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Cronos Group NASDAQ:CRON$2.72 +0.03 (+0.93%) Closing price 06/24/2026 03:58 PM EasternExtended Trading$2.72 0.00 (0.00%) As of 06/24/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Corvus Pharmaceuticals NASDAQ:CRVS$12.96 +0.33 (+2.63%) Closing price 06/24/2026 03:59 PM EasternExtended Trading$13.04 +0.08 (+0.59%) As of 06/24/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.ARS Pharmaceuticals NASDAQ:SPRY$10.54 +0.26 (+2.53%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$8.05 -2.49 (-23.65%) As of 06/24/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
